From the Department of Day Hospitalization, Schneider Children's Medical Center, Petach Tikva, Israel.
Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Pediatr Infect Dis J. 2024 Oct 1;43(10):963-969. doi: 10.1097/INF.0000000000004415. Epub 2024 May 29.
The standard vancomycin regimen for term neonates is 45 mg/kg/day. However, the optimal starting vancomycin dosing for achieving therapeutic levels in young infants in cardiac intensive care units remains unknown. Moreover, data on the association of supratherapeutic vancomycin levels with acute kidney injury (AKI) are limited.
Retrospective study of infants ≤3 months old, receiving vancomycin following congenital heart surgery at postoperative intensive care unit admission. Assessed were vancomycin dosing, achievement of therapeutic trough concentration of 10-20 mg/L and development of AKI, based on the modified Kidney Disease Improving Global Outcomes criteria.
Inclusion criteria were met by 109 patients with a median age of 8 days (IQR: 6-16). The mean (SD) vancomycin dose required for achieving therapeutic concentration was 28.9 (9.1) mg/kg at the first postoperative day. Multivariate logistic regression identified higher preoperative creatinine levels and shorter cardiopulmonary bypass time as predictors of supratherapeutic vancomycin concentrations (c-index 0.788). During the treatment course, 62 (56.9%) developed AKI. Length of stay and mortality were higher in those who developed AKI as compared with those who did not. Multivariate logistic regression identified higher vancomycin concentration as a predictor for postoperative AKI, OR, 3.391 (95% CI: 1.257-9.151), P = 0.016 (c-index 0.896).
Our results support a lower starting vancomycin dose of ~30 mg/kg/day followed by an early personalized therapeutic approach, to achieve therapeutic trough concentrations of 10-20 mg/L in cardiac postoperative term infants. Supratherapeutic concentrations are associated with an increased risk for AKI, which is prevalent in this population and associated with adverse outcomes.
足月新生儿万古霉素的标准治疗方案为 45mg/kg/天。然而,心脏重症监护病房中婴幼儿达到治疗水平的最佳万古霉素起始剂量仍不清楚。此外,关于超治疗范围的万古霉素水平与急性肾损伤(AKI)的关系的数据有限。
对心脏手术后在重症监护病房入院时接受万古霉素治疗的≤3 个月龄婴儿进行回顾性研究。评估了万古霉素的剂量、治疗谷浓度 10-20mg/L 的达标情况以及 AKI 的发生情况,AKI 的诊断依据改良的肾脏病改善全球结局标准。
纳入标准为 109 名婴儿,中位年龄为 8 天(IQR:6-16)。第 1 天术后达到治疗浓度所需的万古霉素平均(SD)剂量为 28.9(9.1)mg/kg。多变量逻辑回归确定术前肌酐水平较高和体外循环时间较短是超治疗范围万古霉素浓度的预测因素(c 指数 0.788)。在治疗过程中,62 例(56.9%)发生 AKI。与未发生 AKI 的患者相比,发生 AKI 的患者的住院时间和死亡率更高。多变量逻辑回归确定较高的万古霉素浓度是术后 AKI 的预测因素,比值比为 3.391(95%CI:1.257-9.151),P=0.016(c 指数 0.896)。
我们的研究结果支持起始万古霉素剂量约为 30mg/kg/天,随后采用早期个体化治疗方法,使心脏术后足月婴儿达到治疗谷浓度 10-20mg/L。超治疗范围的浓度与 AKI 的风险增加相关,而 AKI 在该人群中较为常见,并与不良结局相关。